Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Clinipace has hired four operational, therapeutic, and medical experts to bolster the company’s global strategic development capabilities and medical expertise.
read more
Lumos Diagnostics and RPS Diagnostics announced they have merged. The combined company will be called Lumos Diagnostics.
read more
Zymeworks has earned a milestone payment from Merck achieved under the companies’ 2014 research and license agreement.
read more
ReForm Biologics announced the appointment of Alan Herman, Ph.D. and Fred Larimore, Ph.D. to the company’s Scientific Advisory Board (SAB).
read more
Teva Pharmaceutical announced the launch of a generic version of Ranexa® (ranolazine) Extended-Release Tablets, 500 mg and 1000 mg, in the U.S.
read more
Scientist.com has announced a partnership with 5AM Ventures, a venture capital firm focused on building next-generation life science companies.
read more
Boehringer Ingelheim and Gubra announce a second collaboration and license agreement for the development of novel poly-agonist peptides to treat obesity.
read more
Macrogen has received GCLP (Good Clinical Laboratory Practice) accreditation from the Ministry of Food and Drug Safety (MFDS) in Korea.
read more
Effective immediately, all Vetter sites in Germany will be supplied with only CO2 neutral energy from certified renewable energy sources.
read more
Integral Molecular has successfully reached the first milestone in its collaboration with Daiichi Sankyo to discover new immuno-oncology (I-O) therapeutic targets.
read more
Synaffix announced that ADC Therapeutics has triggered a third target-specific license under its existing Commercial License Agreement dated October 2016.
read more
Armas Pharmaceuticals and Micro Labs USA have announced the forming of a strategic collaboration to bring select multisource injectable products to the U.S. market.
read more
MMS Holdings announced the addition of Dr. Mike Poole, MD, FACP to its board of scientific advisors.
read more
Particle Sciences has broadened its Drug Enforcement Administration (DEA) registration to become an authorized manufacturer of Schedule I substances.
read more
Veratrak has announced that CPO Central Pharma has selected its platform to help it achieve digitized end-to-end visibility of its supply chain and improve collaboration.
read more